Behavioural Neurology

Behavioural Neurology / 2009 / Article
Special Issue

Alzheimer’s Disease and Mild Cognitive Impairment: New Insights from Imaging

View this Special Issue

Open Access

Volume 21 |Article ID 836437 |

Adam S. Fleisher, Michael Donohue, Kewei Chen, James B. Brewer, Paul S. Aisen, the Alzheimer’s Disease Neuroimaging Initiative, "Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease", Behavioural Neurology, vol. 21, Article ID 836437, 8 pages, 2009.

Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease

Received16 Oct 2009
Accepted16 Oct 2009


Critical to development of new therapies for Alzheimer’s disease (AD) is the ability to detect clinical or pathological change over time. Clinical outcome measures typically used in therapeutic trials have unfortunately proven to be relatively variable and somewhat insensitive to change in this slowly progressive disease. For this reason, development of surrogate biomarkers that identify significant disease-associated brain changes are necessary to expedite treatment development in AD. Since AD pathology is present in the brain many years prior to clinical manifestation, ideally we want to develop biomarkers of disease that identify abnormal brain structure or function even prior to cognitive decline. Magnetic resonance imaging, fluorodeoxyglucose positron emission tomography, new amyloid imaging techniques, and spinal fluid markers of AD all have great potential to provide surrogate endpoint measures for AD pathology. The Alzheimer’s disease neuroimaging initiative (ADNI) was developed for the distinct purpose of evaluating surrogate biomarkers for drug development in AD. Recent evidence from ADNI demonstrates that imaging may provide more sensitive, and earlier, measures of disease progression than traditional clinical measures for powering clinical drug trials in Alzheimer's disease. This review discusses recently presented data from the ADNI dataset, and the importance of imaging in the future of drug development in AD.

Copyright © 2009 Hindawi Publishing Corporation and the authors. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Order printed copiesOrder

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.